Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.46 |
| ▸ | TUBB | P07437 | 2/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772827 | 0.81 | ALDH1A1 (0.97) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL31718101 | 0.81 | ALDH1A1 (0.97) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL4768926 | 0.81 | KDM4E (0.63) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL1536353 | 0.80 | KDM4E (0.64) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL1536571 | 0.77 | CLK1 (0.48) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL4773470 | 0.76 | PARP1 (0.58) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL1536341 | 0.76 | PARP15 (0.49) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL1536468 | 0.76 | KDM4E (0.58) | RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1536409 | 0.73 | CDC25B (0.43) | RAB9ALMNANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL1536331 | 0.73 | PDE3B (0.43) | RAB9ALMNANPC1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2086963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20060172950-A1 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | WANG XIANGDONG A | 2006-08-03 | — | — | US | disclosed |
| EP-1629000-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6995174-B2 | for inhibiting proteases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | RAB9A 703/4885LMNA 2968/4885NPC1 458/4885 |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | VIP, QPCT, HCCS | RAB9A 148/4885LMNA 3597/4885NPC1 497/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | RAB9A 617/4885LMNA 3504/4885NPC1 378/4885 |
| US-20060172950-A1 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | PRSS1, CTRL, CTRB1 | RAB9A 1039/4885LMNA 1949/4885NPC1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.